Harrow Inc (HROW)
17.97
+0.03
(+0.17%)
USD |
NASDAQ |
Jun 14, 16:00
17.98
+0.01
(+0.06%)
After-Hours: 20:00
Harrow SG&A Expense (Quarterly): 28.81M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 28.81M |
December 31, 2023 | 26.21M |
September 30, 2023 | 21.03M |
June 30, 2023 | 19.96M |
March 31, 2023 | 15.89M |
December 31, 2022 | 15.24M |
September 30, 2022 | 15.42M |
June 30, 2022 | 14.18M |
March 31, 2022 | 13.40M |
December 31, 2021 | 12.67M |
September 30, 2021 | 11.36M |
June 30, 2021 | 9.123M |
March 31, 2021 | 8.164M |
December 31, 2020 | 7.441M |
September 30, 2020 | 8.436M |
June 30, 2020 | 6.954M |
March 31, 2020 | 8.416M |
December 31, 2019 | 7.689M |
September 30, 2019 | 8.608M |
June 30, 2019 | 8.248M |
March 31, 2019 | 8.543M |
December 31, 2018 | 9.012M |
September 30, 2018 | 6.964M |
June 30, 2018 | 6.779M |
March 31, 2018 | 6.488M |
Date | Value |
---|---|
December 31, 2017 | 5.942M |
September 30, 2017 | 5.781M |
June 30, 2017 | 6.485M |
March 31, 2017 | 6.811M |
December 31, 2016 | 5.629M |
September 30, 2016 | 6.815M |
June 30, 2016 | 6.667M |
March 31, 2016 | 5.84M |
December 31, 2015 | 6.218M |
September 30, 2015 | 4.917M |
June 30, 2015 | 4.373M |
March 31, 2015 | 3.492M |
December 31, 2014 | 2.852M |
September 30, 2014 | 2.591M |
June 30, 2014 | 2.758M |
March 31, 2014 | 2.277M |
December 31, 2013 | 1.882M |
September 30, 2013 | 1.623M |
June 30, 2013 | 1.556M |
March 31, 2013 | 1.020M |
December 31, 2012 | 0.7404M |
September 30, 2012 | 0.9464M |
June 30, 2012 | 0.9847M |
March 31, 2012 | 0.309M |
December 31, 2011 | 0.3131M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
6.954M
Minimum
Jun 2020
28.81M
Maximum
Mar 2024
13.36M
Average
12.01M
Median
SG&A Expense (Quarterly) Benchmarks
Durect Corp | 3.136M |
Aquestive Therapeutics Inc | 10.69M |
Cyclacel Pharmaceuticals Inc | 1.582M |
Stereotaxis Inc | 6.469M |
Cara Therapeutics Inc | 6.786M |